SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BEARISH
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▼ Bearish

Expect REGN to trade down 3-6% on this Phase 3 miss as the market prices out near-term regulatory filing probability. The ongoing Opdualag head-to-head trial remains a binary catalyst but now carries higher risk. Traders should watch for analyst downgrades and potential pipeline re-rating.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$629.34
T+0 close · May 15, 2026 · via day close
Latest settled
+26.80%
T+60 · $797.99
Vs SPY
+22.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $629.34entry
  2. T+1 · 6mo ago +0.07%α +0.72% · $629.76
  3. T+5 · 6mo ago +0.45%α −1.17% · $632.17
  4. T+20 · 5mo ago −2.28%α −4.47% · $614.98
  5. T+60 · 3mo ago +26.80%α +22.22% · $797.99

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron announced that its Phase 3 trial of fianlimab (LAG-3 inhibitor) plus cemiplimab in first-line melanoma did not meet the primary endpoint of statistically significant improvement in progression-free survival (PFS) versus pembrolizumab monotherapy (p=0.0627). A numeric 5.1-month median PFS improvement was observed for the high-dose combination (11.5 vs 6.4 months), but the p-value missed the significance threshold. A head-to-head Phase 3 trial versus Opdualag is ongoing, but this miss reduces the probability of near-term regulatory filing and commercial upside for the combination.

Key Facts

  • Phase 3 trial of fianlimab + cemiplimab in first-line melanoma missed primary endpoint of PFS improvement vs pembrolizumab (p=0.0627).
  • High-dose combination showed numeric 5.1-month median PFS improvement (11.5 vs 6.4 months) but did not reach statistical significance.
  • Low-dose combination hazard ratio 0.931 (p=0.4661), no signal of benefit.
  • No new safety signals identified.
  • A Phase 3 head-to-head trial versus Opdualag (nivolumab + relatlimab) is ongoing.
  • Regeneron is a $74.7B market cap biotech with diversified pipeline, so this miss is significant but not existential.

Financial Impact

The miss delays or eliminates a potential $1B+ peak-sales opportunity in first-line melanoma.

pipeline valueregulatory timelinecompetitive positioning in melanoma

Risk Factors

  • Ongoing Phase 3 head-to-head trial versus Opdualag could also fail, further impairing fianlimab's value.
  • Competitive landscape: Opdualag (BMS) already approved in first-line melanoma; Keytruda (Merck) is standard of care.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296192

Track record

53 reports on REGN

Performance horizon

10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026